Truthfully, I don't know much about industry including salaries etc. However, I think you will find that you rise to a much better position (power, renumeration, people supervised etc.) the later you enter industry, even if all you do is wait until you get an assistant professor head of lab position. The chief scientific officers of many biotech/pharma companies are recruited from academia. Fishman at Novartis and Peter Kim at Merck and Tessier-Lavigne at Genetech and Perlmutter at Merck-->Amgen etc. Fishman and Perlmutter have M.D.s or MD/PhDs.
If you go straight into industry without clinical training +/- postdoc, you don't have very much unique to offer a company. You can join the queue with everyone else waiting for the guy above him/her to die/retire or you can try to transfer horizontally between companies. However, it seems to me that the entry level pay will not be remarkable: you certainly are not entitled to "clinical compensation" pay like the way NIH bumps up the salary of clinically trained individuals. When you work at an entry level staff scientist position, your success will be linked to the small world that you work on in the lab (note the frightening similarity to a basic science postdoc). Your M.D. credentials may or may not help you approach a problem better, but I would be surprised if you were promoted "just because" you have an MD/PhD. If you wait, you come in at a more senior position, you are effectively more diversified in career risk and take the credit for whatever works (note the similarity to a head of lab position).
Another route to industry would be along the lines of clinical research, drug trials, and clinical/regulatory affairs in pharmaceutical companies. These positions require clinical training. I have no evidence to back this up, but I am under the impression that they pay reasonably. I am unclear how difficult it would be to lick you way to the top of the ice cream cone from there. A lot of the pharmaceutical/biotech companies I am familiar with are led by the scientists or businessmen, not the "clinical affairs" guy. Also, (personal editorial), clinical drug development sounds boring as dirt to me. It seems to me all the intellectual action is occuring in the lab there.